Status:
COMPLETED
LSD Therapy for Persons Suffering From Major Depression
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Department of Psychiatry Basel (UPK Basel; Prof. Dr. med. Stefan Borgwardt)
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
25+ years
Phase:
PHASE2
Brief Summary
Background: Major Depressive Disorder is one of the most prevalent mental illnesses, leading to substantial personal distress and economical consequences. Pharmacological Treatment is limited and rela...
Eligibility Criteria
Inclusion
- Major Depressive Disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
- \> 25 years
- Sufficient understanding of the German language
Exclusion
- \< 25 years
- Concomitant diagnosis of past or present psychotic disorder
- Concomitant diagnosis of past or present bipolar disorder
- First degree relative with a psychotic disorder
- Unable or unwilling to discontinue antidepressant medication
- Pregnancy or breastfeeding
- Known hypersensitivity to LSD
- Somatic disorders including central nervous system (CNS) involvement
- Known or suspected non-compliance, drug or alcohol abuse
- Metal implants
- Weight \< 42 kg
- Suicide risk or very likely to require psychiatric hospitalisation
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03866252
Start Date
November 1 2019
End Date
December 1 2022
Last Update
April 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitäre Psychiatrische Kliniken
Basel, Canton of Basel-City, Switzerland, 4002